In H1-23, NAV per share stood at €221.3, compared with €199.5 at end-2022, up 12.4% with dividends reinvested. Listed investments outperformed the markets, thanks in particular to Stellantis (+31% ytd), the valuation of co-investments was boosted by the sale of Polyplus (gene therapy, multiple of 3.8x, IRR: 62%) to Sartorius, and that of investment funds was stable. This performance was achieved despite the downward revision of property assets (11% of the GAV at the end of 2022).
Net debt came to €862m, including €152m for the investment in Rothschild & Co in H2. LTV stood at 14%, down on H1, which bodes well for the future. It should be remembered that all debt is at a fixed rate.
The Group’s discount remains high at 54%, illustrating investors’ mistrust of investment companies with low liquidity. Management is aware of this situation and may consider buying back shares to try to reduce it. Compared with other comparable companies, PEUG’s stock market performance was satisfactory in H1-2023 (+13%).
With an unchanged discount, our central scenario shows a potential upside of 31%. Upload the report